Do you want to read an article? Please log in or register.
Cholinergic system and neuroinflammation: Implication in multiple sclerosis
Aging and Cognitive FunctionsMultiple SclerosisPsychosis and Schizophrenia
Related content
Multiple Sclerosis
Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients
J Neuroinflammation.
Lalive PH, Kreutzfeldt M, Devergne O, Metz I, Bruck W, Merkler D, Pot C
doi: 10.1186/s12974-017-0919-1.
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies
Ann Neurol.
Maggi P, Absinta M, Grammatico M, Vuolo L, Emmi G, Carlucci G, Spagni G, Barilaro A, Repice AM, Emmi L, Prisco D, Martinelli V, Scotti R, Sadeghi N, Perrotta G, Sati P, Dachy B, Reich DS, Filippi M, Massacesi L
doi: 10.1002/ana.25146.
Multiple Sclerosis
Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
J Neurol.
Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).
doi: 10.1007/s00415-019-09563-y.
Multiple Sclerosis
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Brain.
Correale J, Gaitán MI, Ysrraelit MC, Fiol MP
doi: 10.1093/brain/aww258.
RECOMMENDED
Multiple Sclerosis
How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis
Mult Scler.
Barin L, Kamm CP, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry.
doi: 10.1177/
Multiple Sclerosis
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Ther Adv Neurol Disord
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG).
doi: 10.1177/17562864211039648
RECOMMENDED
Multiple Sclerosis
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L
doi: 10.1016/S1474-4422(19)30391-6.